{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:54:38Z","timestamp":1770324878046,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bohringer Ingelheim"},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T08:21:57Z","timestamp":1562746917000},"page":"5009-5015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents"],"prefix":"10.1016","volume":"37","author":[{"given":"Si","family":"Si","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Zomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2019.07.008_b0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOP.0b013e32832c9668","article-title":"Neisseria meningitidis: epidemiology, treatment and prevention in adolescents","volume":"21","author":"Brigham","year":"2009","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.008_b0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.008_b0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/eri.13.42","article-title":"The burden and impact of severe and long-term sequelae of meningococcal disease","volume":"11","author":"Vyse","year":"2013","journal-title":"Expert Rev Anti-infective Therapy"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.008_b0020","doi-asserted-by":"crossref","first-page":"E503","DOI":"10.33321\/cdi.2016.40.57","article-title":"Australian Meningococcal Surveillance Programme annual report, 2015","volume":"40","author":"Lahra","year":"2016","journal-title":"Commun Dis Intell Quart Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.008_b0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.5694\/mja16.01340","article-title":"Epidemiology of invasive meningococcal B disease in Australia, 1999\u20132015: priority populations for vaccination","volume":"207","author":"Archer","year":"2017","journal-title":"Med J Australia"},{"key":"10.1016\/j.vaccine.2019.07.008_b0030","unstructured":"Australian Government DoH. Invasive meningococcal disease national surveillance report; 2017."},{"key":"10.1016\/j.vaccine.2019.07.008_b0035","unstructured":"National centre for immunisation research and surveillance. Meningococcal vaccines for Australians: information for immunisation providers; 2018."},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.008_b0040","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"issue":"29","key":"10.1016\/j.vaccine.2019.07.008_b0045","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis","volume":"25","author":"De Wals","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.008_b0050","doi-asserted-by":"crossref","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","article-title":"Meningococcal serogroup A, C, W135 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands","volume":"8","author":"Hepkema","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.07.008_b0055","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (version 5.0). Australian Government Department of Health; 2016. 2018."},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.008_b0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/aje\/kwq126","article-title":"Long-term mortality in patients diagnosed with pneumococcal meningitis: a Danish nationwide cohort study","volume":"172","author":"Roed","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.008_b0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/INF.0000000000000043","article-title":"The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children","volume":"33","author":"Wang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"34","key":"10.1016\/j.vaccine.2019.07.008_b0070","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2017.06.085","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians","volume":"35","author":"Dirmesropian","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.008_b0075","unstructured":"IHPA. National Hospital Cost Data Collection Australian Public Hospitals Cost Report Round 18, Public Section 2013-2014; 2017."},{"key":"10.1016\/j.vaccine.2019.07.008_b0080","first-page":"2012","article-title":"Patterns and costs of health care use of children with medical complexity","author":"Cohen","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.07.008_b0085","unstructured":"Australian Institute of Health and Welfare. Health expenditure Australia 2014\u201315. Canberra: AIHW; 2016."},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/1753-6405.12004","article-title":"Population norms for the AQoL derived from the 2007 Australian National Survey of Mental Health and Wellbeing","volume":"37","author":"Hawthorne","year":"2013","journal-title":"Aust N Z J Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes","volume":"155","author":"Carroll","year":"2009","journal-title":"J Pediatrics"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.008_b0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1071\/NB10046","article-title":"School-based vaccination in NSW","volume":"21","author":"Ward","year":"2010","journal-title":"New South Wales Public Health Bull"},{"issue":"11","key":"10.1016\/j.vaccine.2019.07.008_b0105","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1017\/S0950268816000704","article-title":"Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme","volume":"144","author":"Lawrence","year":"2016","journal-title":"Epidemiol Infect"},{"issue":"7385","key":"10.1016\/j.vaccine.2019.07.008_b0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"issue":"37","key":"10.1016\/j.vaccine.2019.07.008_b0115","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","article-title":"The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children","volume":"32","author":"Wang","year":"2014","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2019.07.008_b0120","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.vaccine.2014.07.096","article-title":"Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada","volume":"32","author":"Tu","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"\u00d8stergaard","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.008_b0135","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1016\/j.ijid.2012.04.006","article-title":"The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine","volume":"16","author":"Dbaibo","year":"2012","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2019.07.008_b0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4161\/hv.20211","volume":"8","author":"Dbaibo","year":"2012","journal-title":"Human Vacc Immunotherapeut"},{"issue":"7","key":"10.1016\/j.vaccine.2019.07.008_b0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.20212","article-title":"The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults","volume":"8","author":"Reyes","year":"2012","journal-title":"Human Vacc Immunotherapeut"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.008_b0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Human Vacc"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.008_b0155","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.vaccine.2011.11.051","article-title":"A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix\u00ae in subjects aged 11\u201317 years: An open, randomised, controlled trial","volume":"30","author":"\u00d8stergaard","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.008_b0160","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.008_b0165","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1128\/CVI.00162-13","article-title":"Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years","volume":"20","author":"Lupisan","year":"2013","journal-title":"Clin Vacc Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the safety and immunogenicity of a novel quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine and a marketed quadrivalent meningococcal ACWY-diphtheria toxoid conjugate vaccine in healthy individuals 10\u201325 years of age","volume":"3","author":"Halperin","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.008_b0175","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1128\/CVI.00099-14","article-title":"Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom","volume":"21","author":"Ramasamy","year":"2014","journal-title":"Clin Vacc Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.008_b0180","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/archinte.1984.00350200107016","article-title":"Bacterial meningitis in the elderly","volume":"144","author":"Gorse","year":"1984","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.008_b0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1993.00540060015010","article-title":"Spectrum of complications during bacterial meningitis in adults: results of a prospective clinical study","volume":"50","author":"Pfister","year":"1993","journal-title":"Arch Neurol"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2019.07.008_b0190","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1542\/peds.2007-1115H","article-title":"Projected cost-effectiveness of new vaccines for adolescents in the United States","volume":"121","author":"Ortega-Sanchez","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.008_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med Decis Making"},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.008_b0200","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5694\/mja13.10272","article-title":"Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach","volume":"199","author":"Brotherton","year":"2013","journal-title":"Med J Aust"},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.008_b0205","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2471\/BLT.11.086538","article-title":"The impact of adolescent pertussis immunization, 2004\u20132009: lessons from Australia","volume":"89","author":"Quinn","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.008_b0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1355819617751816","article-title":"The political economy of the assessment of value of new health technologies","volume":"23","author":"Karnon","year":"2018","journal-title":"J Health Serv Res Policy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:38Z","timestamp":1759401218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":42,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19308862"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}